Search results
Results from the WOW.Com Content Network
Zilucoplan is a cyclic peptide that binds to the protein complement component 5 (C5) and inhibits its cleavage into C5a and C5b. [11] Zilucoplan was approved for medical use in the United States in October 2023, [6] [12] in the European Union in December 2023, [7] and in Australia in July 2024. [1]
Geroscience has a long way to go, but there are four FDA-approved drugs that have shown promise to “target the process of aging,” Barzilai says. While not approved as anti-aging treatments ...
Cilengitide (EMD 121974) is a molecule designed and synthesized at the Technical University Munich in collaboration with Merck KGaA in Darmstadt.It is based on the cyclic peptide cyclo(-RGDfV-), which is selective for α v integrins, which are important in angiogenesis (forming new blood vessels), and other aspects of tumor biology.
Peptide therapeutics are peptides or polypeptides (oligomers or short polymers of amino acids) which are used to for the treatment of diseases.Naturally occurring peptides may serve as hormones, growth factors, neurotransmitters, ion channel ligands, and anti-infectives; peptide therapeutics mimic such functions.
The medication is a peptide and acts by activating the melanocortin receptors. [1] [5] Bremelanotide was approved for medical use in the United States in 2019. [2] [6] It was developed by Palatin Technologies. [7] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [8]
Setmelanotide, sold under the brand name Imcivree, is a medication used for the treatment of genetic obesity caused by a rare single-gene mutation. [4] [5] [6]The most common side effects include injection site reactions, skin hyperpigmentation (skin patches that are darker than surrounding skin), headache and gastrointestinal side effects (such as nausea, diarrhea, and abdominal pain), among ...
N-Phenylacetyl-l-prolylglycine ethyl ester is promoted as a nootropic and is a prodrug of cyclic glycine-proline. [a] [2] Other names include the brand name Noopept (Russian: Ноопепт), developmental code GVS-111, and proposed INN omberacetam.
The rights to LY 146032 were acquired by Cubist Pharmaceuticals in 1997, which following U.S. Food and Drug Administration (FDA) approval in September 2003, for use in people older than 18 years, began marketing the drug under the trade name Cubicin.